--- title: "Heamonetics | 8-K: FY2027 Q1 Revenue Beats Estimate at USD 339.38 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295088819.md" datetime: "2026-08-06T10:12:32.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295088819.md) - [en](https://longbridge.com/en/news/295088819.md) - [zh-HK](https://longbridge.com/zh-HK/news/295088819.md) generator: "portal-rs" --- # Heamonetics | 8-K: FY2027 Q1 Revenue Beats Estimate at USD 339.38 M Revenue: As of FY2027 Q1, the actual value is USD 339.38 M, beating the estimate of USD 327.89 M. EPS: As of FY2027 Q1, the actual value is USD 0.72, missing the estimate of USD 0.7333. EBIT: As of FY2027 Q1, the actual value is USD 57.46 M. #### Total Revenue Reported revenue for the first quarter of fiscal 2027 was $339.4 million, marking a 5.6% increase compared to the first quarter of fiscal 2026. Organic revenue growth for the quarter was 5.9% compared to the same period of fiscal 2026. #### Segment Revenue (Reported) - **Apheresis**: Revenue was $191.3 million, an increase of 5.3% year-over-year. - Plasma revenue reached $155.524 million, up 7.2%. - Other revenue was $35.794 million, representing a decrease of -2.4%. - **MedSurg**: Revenue totaled $148.062 million, an increase of 6.0% year-over-year. - Interventional Technologies revenue was $59.942 million, up 2.5%. - Blood Management Technologies revenue amounted to $88.120 million, up 8.6%. #### Segment Organic Revenue Growth - **Apheresis**: Experienced 6.0% organic revenue growth. - **MedSurg**: Experienced 5.9% organic revenue growth. #### Gross Margin GAAP gross margin was 59.8% in the first quarter of fiscal 2027, remaining flat compared to 59.8% in the first quarter of fiscal 2026. Adjusted gross margin was 60.4%, a decrease of -40 basis points compared to the prior year period. #### Operating Expenses GAAP operating expenses were $145.3 million, an increase of $7.0 million or 5.0% compared to the first quarter of fiscal 2026, driven by higher personnel-related costs and freight charges. Adjusted operating expenses were $125.6 million, an increase of $7.9 million or 6.7% compared to the first quarter of fiscal 2026, also due to higher personnel-related costs and freight charges. #### Operating Income GAAP operating income was $57.5 million, up 6.7% from $53.9 million in the first quarter of fiscal 2026. Adjusted operating income was $79.3 million, a decrease of -$1.7 million or -2.2% compared to the first quarter of fiscal 2026. #### Operating Margin GAAP operating margin was 16.9%, up 0.1% from 16.8% in the first quarter of fiscal 2026. Adjusted operating margin was 23.4%, down -70 basis points compared to the same period of fiscal 2026. #### Net Income GAAP net income was $33.0 million, a decrease of -3.0% from $34.0 million in the first quarter of fiscal 2026. Adjusted net income was $52.3 million, an increase of $0.9 million or 1.8% compared to the first quarter of fiscal 2026. #### Effective Income Tax Rate The GAAP effective income tax rate was 30.6% in the first quarter of fiscal 2027, compared to 24.7% in the first quarter of fiscal 2026. The adjusted income tax rate for the first quarter of fiscal 2027 was 25.7%, up 180 basis points from 24.9% in the prior year period. #### Cash Flow Cash flow from operating activities was $52.3 million, an increase of $34.9 million compared to $17.395 million in the first quarter of fiscal 2026. Free cash flow was $39.1 million, an increase of $36.6 million compared to $2.478 million in the first quarter of fiscal 2026. #### Cash on Hand Cash on hand as of June 27, 2026, was $223.4 million, a decrease of -$22.1 million since the end of fiscal 2026. #### Fiscal 2027 Guidance Haemonetics Corporation raised its fiscal 2027 GAAP revenue and organic revenue growth guidance, now expecting reported revenue growth of 5-8% and organic revenue growth of 4-7% for the full year. The company projects adjusted operating margin to expand by 50-100 basis points year-over-year. Free cash flow conversion is anticipated to be approximately 80%. ### Related Stocks - [HAE.US](https://longbridge.com/en/quote/HAE.US.md) ## Related News & Research - [Is Haemonetics’ (HAE) ESOP Shelf Move Reframing Its Balance Between Growth Investment and Shareholder Dilution?](https://longbridge.com/en/news/296298828.md) - [Haemonetics signs non-exclusive US plasma supply deal with CSL Plasma for NexSys PCS devices, disposables](https://longbridge.com/en/news/296210402.md) - [TJX Q2 2027 earnings preview](https://longbridge.com/en/news/296255341.md) - [09:03 ETThe Princeton Review's "Best Colleges for 2027" Rankings Are Out](https://longbridge.com/en/news/296233129.md) - [First Trust High Yield Opportunities 2027 Term Fund declares monthly distribution of $0.125 a share for September](https://longbridge.com/en/news/296531419.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**